Matrix Biomed, Inc. is a biopharmaceutical company focused on improved drug development through genetic profiling. Gene-based therapeutics target both the dysregulation of one or more genes, as well as gene-gene interactions. Matrix Biomed, Inc. redefines disease models by establishing extensive gene regulatory networks and gene co-expression networks that identify abnormal gene expression in the disease, relative to a healthy state. By redefining human diseases within these networks, Matrix Biomed, Inc. develops therapeutic formulations of compounds shown to restore the abnormally expressed genes to the healthy state. By establishing the genes involved in the disease mechanism, Matrix Biomed, Inc. accelerates the discovery and identification of novel therapeutic approaches to efficiently treat the disease without unappreciated negative side effects.

Matrix Biomed, Inc. departs with standard industry practices by extensively exploring the functional connection between drugs, genes, and diseases. By departing with these practices, Matrix Biomed, Inc.’s objective is to increase the relatively low rate at which novel drug candidates are translated into effective clinical therapies. With an average development timeframe of 15 years, a cost of over 1 billion U.S., and a success rate of less than ten percent for discovery of a single novel drug, the pharmaceutical industry is in dire need of reformed models and practices. Only by addressing the dysregulation of multiple genes and their interactions in gene regulatory networks, Matrix Biomed, Inc. is able to deliver a therapy designed to truly revert a disease state to healthy state.

Currently, Matrix Biomed, Inc. gene-based therapeutics has produced drug products with two main objectives : 1) increase the efficacy of current cancer treatment regimens and 2) decrease side effects of chemotherapy and radiation. By targeting the master genes responsible for cancer development and progression (HIF-1 and HIF-2), Matrix Biomed, Inc. is poised to transform cancer treatment.